Deltagen Valuation
| DGEN Stock | USD 0.0001 0.00 0.00% |
Deltagen seems to be overvalued based on Macroaxis valuation methodology. Our model computes the value of Deltagen from reviewing the firm fundamentals such as Price To Sales of 0.04 X, current valuation of 71.64 K, and Profit Margin of (0.06) % as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Deltagen's price fluctuation is very steady at this time. Calculation of the real value of Deltagen is based on 3 months time horizon. Increasing Deltagen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Deltagen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Deltagen Pink Sheet. However, Deltagen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.4E-5 | Hype 1.0E-4 |
The intrinsic value of Deltagen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Deltagen's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Deltagen helps investors to forecast how Deltagen pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Deltagen more accurately as focusing exclusively on Deltagen's fundamentals will not take into account other important factors: Deltagen Total Value Analysis
Deltagen is currently forecasted to have valuation of 71.64 K with market capitalization of 27.46 K, debt of 0, and cash on hands of 23 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Deltagen fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
71.64 K | 27.46 K | 0 | 23 K |
Deltagen Investor Information
The company has Price/Earnings To Growth (PEG) ratio of 1.37. Deltagen last dividend was issued on the 17th of May 2007. Based on the analysis of Deltagen's profitability, liquidity, and operating efficiency, Deltagen is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Deltagen Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Deltagen has an asset utilization ratio of 42.8 percent. This suggests that the Company is making $0.43 for each dollar of assets. An increasing asset utilization means that Deltagen is more efficient with each dollar of assets it utilizes for everyday operations.Deltagen Profitability Analysis
The company reported the previous year's revenue of 770 K. Net Loss for the year was (46 K) with profit before overhead, payroll, taxes, and interest of 766 K.About Deltagen Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Deltagen. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Deltagen based exclusively on its fundamental and basic technical indicators. By analyzing Deltagen's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Deltagen's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Deltagen. We calculate exposure to Deltagen's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Deltagen's related companies.Deltagen, Inc. provides drug discovery tools and services to the biopharmaceutical industry and to the academic research community in the United States. The company was founded in 1997 and is headquartered in San Mateo, California. Deltagen operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Deltagen's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Deltagen's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Deltagen's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Deltagen's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Deltagen's revenue streams: Identify Deltagen's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Deltagen's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Deltagen's growth potential: Evaluate Deltagen's management, business model, and growth potential.
- Determine Deltagen's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Deltagen's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Deltagen Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Forward Price Earnings | 21.9298 | |
| Retained Earnings | -228.5 M |
Other Information on Investing in Deltagen Pink Sheet
Deltagen financial ratios help investors to determine whether Deltagen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Deltagen with respect to the benefits of owning Deltagen security.